Clinical Trial Details
Braintumor Website

[Information provided by:, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT02698280 : Bevacizumab and Nimustine in Patients With Recurrent High Grade Glioma
PhasePhase 2
AgesMin: 18 Years Max: 75 Years
Inclusion Criteria:

- Histological diagnosis of primary tumor as high-grade gliomas (WHO III or IV)

- All patients should complete radiotherapy and chemotherapy for primary gliomas

- Enhanced MRI and magnetic resonance spectroscopy showed unequivocal evidence of tumor
recurrence or progression.

- Those patients underwent surgical resection after tumor recurrence can also be
enrolled if histological diagnosis of GBM is available, and MRI within 3 days after
operation is needed.

- The patients with recurrent gliomas didn't undergo bevacizumab therapy before

- The time to be enrolled should be more than 90 days after the radiation therapy, more
than 28 days after operation for recurrent tumor or prior chemotherapy.

- Eastern Cooperative Oncology Group score: 0-2

- Written informed consent

- Laboratory test: Neutrophil count > 1.5*10^9/L, platelet count > 100*109/L, hemoglobin
> 8 g/dL, blood urea nitrogen and creatinine < 1.5 upper limit of normal(ULN), blood
total bilirubin and conjugated bilirubin < 1.5 ULN, alanine aminotransferase(ALT) and
aspartate aminotransferase(AST) < 3 ULN, alkaline phosphatase(AKP) < 2 ULN

Exclusion Criteria:

- Pregnant or lactating women

- Allergic to administered drugs

- Radiation therapy in the previous 90 days before enrollment

- The patients with recurrent gliomas were treated with bevacizumab therapy before

- Acute infection in need of antibiotics intravenously

- Participation in other clinical trials in the 90 days before enrollment
LinksPermanent Link to THIS page:      |      Link to official listing

Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2020 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557